Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A Receptor Tyrosine Kinase Plays Separate Roles in Sensory Integration and Associative Learning in C. elegans.

Wolfe GS, Tong VW, Povse E, Merritt DM, Stegeman GW, Flibotte S, van der Kooy D.

eNeuro. 2019 Aug 13;6(4). pii: ENEURO.0244-18.2019. doi: 10.1523/ENEURO.0244-18.2019. Print 2019 Jul/Aug.

2.

Presbyopia: a pilot investigation of the barriers and benefits of near visual acuity correction among a rural Filipino population.

Wubben TJ, Guerrero CM, Salum M, Wolfe GS, Giovannelli GP, Ramsey DJ.

BMC Ophthalmol. 2014 Jan 27;14:9. doi: 10.1186/1471-2415-14-9.

3.
4.

Titrating beyond glycemic goal: "post-glycemic target phenomenon".

King AB, Clark D, Wolfe GS.

J Diabetes Sci Technol. 2013 Jul 1;7(4):1093-4. No abstract available.

5.

The number of basal rates required to achieve near-normal basal glucose control in pump-treated type 2 diabetes.

King AB, Clark D, Wolfe GS.

Diabetes Technol Ther. 2012 Oct;14(10):900-3. Epub 2012 Jul 30.

PMID:
22845649
6.

Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.

King AB, Clark D, Wolfe GS.

Endocr Pract. 2012 Jul-Aug;18(4):558-62. doi: 10.4158/EP12042.OR.

PMID:
22548951
7.

How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus.

King AB, Clark D, Wolfe GS.

Endocr Pract. 2012 May-Jun;18(3):382-6. doi: 10.4158/EP11312.OR.

PMID:
22440988
8.

Accuracy of dosage volume for halfway doses in the Victoza Pen.

King AB, Wolfe GS.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1623-4. No abstract available.

9.

Evaluation of a diabetes specialist-guided primary care diabetes treatment program.

King AB, Wolfe GS.

J Am Acad Nurse Pract. 2009 Jan;21(1):24-30. doi: 10.1111/j.1745-7599.2008.00370.x.

PMID:
19125892
10.

Evaluation of a patient education booklet (SimpleStart) effect on postprandial glucose control in type 2 diabetes.

King AB, Wolfe GS, Armstrong DU.

Diabetes Technol Ther. 2007 Jun;9(3):241-5.

PMID:
17561794
11.

Timing and directions for administration of questionnaires affect outcomes measurement.

Stelmack JA, Babcock-Parziale JL, Head DN, Wolfe GS, Fakhoury NE, Wu SM, Massof RW.

J Rehabil Res Dev. 2006 Sep-Oct;43(6):809-16.

12.

Hepatitis C--who should be treated?

Wolfe GS.

Lippincotts Case Manag. 2005 Jul-Aug;10(4):213-6. No abstract available.

PMID:
16056118
13.

Hepatitis C-diagnosis and treatment.

Wolfe GS.

Lippincotts Case Manag. 2005 May-Jun;10(3):174-6. No abstract available.

PMID:
15931053
14.

Hepatitis C: laboratory tests to be done before the diagnosis can be made.

Wolfe GS.

Lippincotts Case Manag. 2005 Mar-Apr;10(2):115-7. No abstract available.

PMID:
15815230
15.

Hepatitis C: the latest epidemic.

Wolfe GS.

Lippincotts Case Manag. 2005 Jan-Feb;10(1):56-9. No abstract available.

PMID:
15685013
16.

HIV therapeutics: confronting adherence.

Katzenstein DA, Lyons C, Molaghan JP, Ungvarski P, Wolfe GS, Williams A.

J Assoc Nurses AIDS Care. 1997;8 Suppl:46-58. Review. No abstract available.

PMID:
9356962
17.

The case manager's role in adherence.

Wolfe GS.

J Assoc Nurses AIDS Care. 1997;8 Suppl:24-8.

PMID:
9356959
18.

Case management: today and the future.

Wolfe GS.

Med Interface. 1995 Oct;8(10):118, 125. No abstract available.

PMID:
10152317

Supplemental Content

Loading ...
Support Center